Thomas Hansmann/AP/Shutterstock
Share:
- PAXLOVID is the first FDA-approved oral treatment for COVID-19; has been authorized for emergency use since December 2021
- Approval is based on the totality of scientific evidence submitted, including efficacy data from the Phase 2/3 EPIC-HR study showing an 86% reduction in risk of COVID-19-related hospitalization or death from any cause in patients who took PAXLOVID within five days of symptom onset
- PAXLOVID remains available to eligible patients via prescription at no charge
Read the full press release here.
SEE ALSO:
- Contagion live: FDA approves Paxlovid for COVID-19 in adults, continues strategy to minimize infection severity
Source : Pfizer Inc.
Materials
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.